Abstract
A versatile strategy for the intracellular delivery of functional proteins/antibodies was developed using N-terminal site-specific modification. Adopting orthogonal dual-labeling strategies, a cell-permeable RNase A prodrug was designed complementing N-terminal site-specific modification with lysine labeling. Upon successful cytosolic uptake, the prodrug showed reactive oxygen species (ROS)-dependent targeted cancer therapy.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Cell Proliferation / drug effects
-
Cell Survival / drug effects
-
Drug Delivery Systems*
-
Drug Screening Assays, Antitumor
-
Female
-
HeLa Cells
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Optical Imaging
-
Prodrugs / administration & dosage
-
Prodrugs / chemistry
-
Prodrugs / pharmacology*
-
Reactive Oxygen Species / metabolism
-
Ribonuclease, Pancreatic / chemistry
-
Ribonuclease, Pancreatic / metabolism*
-
Uterine Cervical Neoplasms / drug therapy*
-
Uterine Cervical Neoplasms / metabolism
-
Uterine Cervical Neoplasms / pathology
Substances
-
Antineoplastic Agents
-
Prodrugs
-
Reactive Oxygen Species
-
Ribonuclease, Pancreatic